Next Article in Journal
Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications
Next Article in Special Issue
Beyond Genetics—Stratified and Personalised Medicines Using Multiple Parameters
Previous Article in Journal
Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2
Previous Article in Special Issue
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(4), 1122-1138; doi:10.3390/ph3041122

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK
Author to whom correspondence should be addressed.
Received: 30 December 2009 / Revised: 12 March 2010 / Accepted: 9 April 2010 / Published: 15 April 2010
(This article belongs to the Special Issue Personalized Medicine)
View Full-Text   |   Download PDF [241 KB, uploaded 15 April 2010]   |  


Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
Keywords: tamoxifen; CYP2D6 genotyping; breast cancer tamoxifen; CYP2D6 genotyping; breast cancer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ferraldeschi, R.; Newman, W.G. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals 2010, 3, 1122-1138.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top